C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease

Medical and Pediatric Oncology

Volumn 41, Issue 1, 2003, Pages 21-25

  Wieland, Annemarie ^a   Kerbl, Reinhold ^a,c   Berghold, Andrea ^b   Schwinger, Wolfgang ^a   Mann, Georg ^c   Urban, Christian ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

C reactive protein; Cancer in childhood and adolescence; Hodgkin disease; Prognostic index; Tumor marker

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 2 RECEPTOR; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CANCER STAGING; CHILD; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SYMPTOM; AUSTRIA; BLOOD; CLINICAL TRIAL; EVALUATION; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AUSTRIA; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0037734176     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10286     Document Type: Article

References (33)

1. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992;4:361-368.
2. Fassbender K, Dempfle CE, Mielke O, et al. Proinflammatory cytokines: Indicators of infection in high-risk patients. J Lab Clin Med 1997;130:535-539.
3. Franke S, Herrmann D, Hein G, et al. Interleukin-6, soluble interleukin-2-receptor, and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: Influences of disease activity and drug therapy. Eur J Med Res 1997;2:401-406.
4. Herrmann JL, Blanchard H, Brunengo P, et al. TNF alpha, IL-1 beta, and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values. Infection 1994;22:309-315.
5. Kutukculer N, Caglayan S, Aydogdu F. Sludy of proinflammatory (TNF-alpha, IL-1 alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: Correlations with clinical and laboratory parameters. Clin Rheumatol 1998;17:288-292.
6. Volk HD, Reinke P, Docke WD. Immunological monitoring of the inflammatory process: Which variables? When to assess? Eur J Surg Suppl 1999;28:70-72.
7. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
8. Versaci F, Gaspardone A, Tomai F, et al. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 2000;85:92-95.
9. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
10. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 2001;32:133-138.
11. Child JA, Cooper EH, Illingworth S, et al. Biochemical markers in Hodgkin's disease and non-Hodgkin's lymphoma. Recent Results Cancer Res 1978;64:180-189.
12. Child JA, Spati B, Illingworth S, et al. Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: Findings in a multicenter study and experience in selected patients. Cancer 1980;45:318-326.
13. Legouffe E, Rodriguez C, Picot MC, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 1998;31:351-357.
14. Tartour E, Deneux L, Mosseri V, et al. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: Results of a multivariate prospective study. Cancer 1997;79:1401-1408.
15. Nakano T, Chahinian AP, Shinjo M, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998;77:907-912.
16. Kodama J, Miyagi Y, Seki N, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999;82:107-110.
17. Maccio A, Lai P, Santona MC, et al. High serum levels of soluble IL-2 receptor, cytokines, and C-reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998;69:248-252.
18. Ikeda T, Kawakami K, Fujita J, et al. Thymic carcinoma associated with a high serum level of interleukin 6 diagnosed through the evaluation for asymptomatic elevation of acute-phase reactants. Intern Med 1998;37:414-416.
19. Barber MD, Powell JJ, Lynch SF, et al. Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin Exp Immunol 1999;117:425-429.
20. Nozoe T, Matsumata T, Kitamura M, et al. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998;176:335-338.
21. Zaloudik J, Lauerova L, Janakova L, et al. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver. Hepatogastroenterology 1999;46:220-227.
22. Inoue T, Hashimura T, Iwamura H, et al. Multivariate analysis of prognostic determinants after surgery for renal cell carcinoma at Himeji National Hospital. Hinyokika Kiyo 2000;46:229-234.
23. Masuda H, Kurita Y, Fukuta K, et al. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 1998;5:418-422.
24. Wechsel HW, Feil G, Lahme S, et al. Control of hepatic parameters in renal cell carcinoma (RCC) by interleukin-6 (IL-6)? Anticancer Res 1999;19:2577-2581.
25. Zielinski CC, Preis P, Aiginger P, et al. Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin's disease. J Cancer Res Clin Oncol 1985;110:65-70.
26. Ambrosetti A, Nadali G, Vinante F, et al. Serum levels of soluble interleukin-2 receptor in Hodgkin disease: Relationship with clinical stage, tumor burden, and treatment outcome. Cancer 1993;72:201-206.
27. Kalmanti M, Karamolengou K, Dimitriou H, et al. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma. Int J Hematol 1993;57:147-152.
28. Altmann DG. Practical statistics for medical research. London: Chapman and Hall; 1995.
29. Galve-de Rochemonteix B, Wiktorowicz K, Kushner I, et al. C-reactive protein increases production of IL-1 alpha, IL-1 beta, and TNF-alpha, and expression of mRNA by human alveolar macrophages. J Leukoc Biol 1993;53:439-445.
30. Ohzato H, Yoshizaki K, Nishimoto N, et al. Interleukin-6 as a new indicator of inflammatory status: Detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 1992;111:201-209.
31. Biro L, Domjan G, Falus A, et al. Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur J Clin Invest 1998;28:679-686.
32. Jablonska E, Piotrowski L, Grabowska Z. Serum levels of IL-1b, IL-6, TNF-a, sTNF-RI, and CRP in patients with oral cavity cancer. Pathol Oncol Res 1997;3:126-129.
33. Pui CH, Hudson M, Luo X, et al. Serum interleukin-2 receptor levels in Hodgkin disease and other solid tumors of childhood. Leukemia 1993;7:1242-1244.